Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Article Details
- CitationCopy to clipboard
Reddy V, Dahal LN, Cragg MS, Leandro M
Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Drug Discov Today. 2016 Aug;21(8):1330-8. doi: 10.1016/j.drudis.2016.06.009. Epub 2016 Jun 22.
- PubMed ID
- 27343722 [ View in PubMed]
- Abstract
In Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), B-cell depletion therapy using rituximab results in variable clinical responses between individuals, which likely relates to variable B-cell depletion in the presence of immune defects. Outcomes in clinical trials with other type I anti-CD20 mAbs, ocrelizumab and ofatumumab, are comparable to rituximab. A mechanistically different type II mAb, obinutuzumab (OBZ), with greater capacity for B-cell depletion, has recently entered clinical trials in SLE. Here we consider whether type II anti-CD20 mAbs will provide mechanistic advantages to overcome the disease-related immune defects in autoimmune diseases such as SLE.